AY6

5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide

Created:	2018-12-05
Last modified:	2021-03-01

Find Related PDB Entry
1 entries where AY6 is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	51
Chiral Atom Count	0
Bond Count	54
Aromatic Bond Count	17

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
Synonyms	Rimonabant
Systematic Name (OpenEye OEToolkits)	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-~{N}-piperidin-1-yl-pyrazole-3-carboxamide
Formula	C₂₂ H₂₁ Cl₃ N₄ O
Molecular Weight	463.787
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	n2(c(c(C)c(C(=O)NN1CCCCC1)n2)c3ccc(cc3)Cl)c4c(Cl)cc(cc4)Cl
SMILES	CACTVS	3.385	Cc1c(nn(c2ccc(Cl)cc2Cl)c1c3ccc(Cl)cc3)C(=O)NN4CCCCC4
SMILES	OpenEye OEToolkits	2.0.6	Cc1c(n(nc1C(=O)NN2CCCCC2)c3ccc(cc3Cl)Cl)c4ccc(cc4)Cl
Canonical SMILES	CACTVS	3.385	Cc1c(nn(c2ccc(Cl)cc2Cl)c1c3ccc(Cl)cc3)C(=O)NN4CCCCC4
Canonical SMILES	OpenEye OEToolkits	2.0.6	Cc1c(n(nc1C(=O)NN2CCCCC2)c3ccc(cc3Cl)Cl)c4ccc(cc4)Cl
InChI	InChI	1.03	InChI=1S/C22H21Cl3N4O/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13H,2-4,11-12H2,1H3,(H,27,30)
InChIKey	InChI	1.03	JZCPYUJPEARBJL-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank ID	DB06155
Name	Rimonabant
Groups	approved investigational
Description	Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.
Synonyms	Rimonabant Rimonabant hydrochloride
Brand Names	Zimulti Acomplia
Indication	For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m<sup>2</sup>, or patients wih a BMI greater than 27 kg/m<sup>2</sup> with associated risk factors, such as type 2 diabetes or dyslipidaemia.
Categories	Agents producing tachycardia Alimentary Tract and Metabolism Anti-Obesity Agents Antiobesity Preparations, Excl. Diet Products Cannabinoid Receptor Antagonists Cannabinoids and similars Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Neurotransmitter Agents Piperidines Pyrazoles Receptor, Cannabinoid, CB1, antagonists & inhibitors
ATC-Code	A08AX01
CAS number	168273-06-1

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Cannabinoid receptor 1	MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPL...	unknown	antagonist
G-protein coupled receptor 55	MSQQNTSGDCLFDGVNELMKTLQFAVHIPTFVLGLLLNLLAIHGFSTFLK...	unknown
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682